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The long-term prognosis of HIV-2-infected patients receiving antiretroviral therapy (ART) is
still challenging, due to the intrinsic resistance to non-nucleoside reverse transcriptase inhib-
itors (NNRTI) and the suboptimal response to some protease inhibitors (PI). The objective
was to describe the 5-years outcomes among HIV-2 patients harboring drug-resistant
viruses.
Methods
A clinic-based cohort of HIV-2-patients experiencing virologic failure, with at least one drug
resistance mutation was followed from January 2012 to August 2017 in Côte d’Ivoire. Fol-
low-up data included death, lost to follow-up (LTFU), immuno-virological responses. The
Kaplan-Meier curve was used to estimate survival rates.
Results
A total of 31 HIV-2 patients with virologic failure and with at least one drug resistance muta-
tion were included. Two-third of them were men, 28(90.3%) were on PI-based ART-regimen
at enrolment and the median age was 50 years (IQR = 46–54). The median baseline CD4
count and viral load were 456 cells/mm3 and 3.7 log10 c/mL respectively, and the partici-
pants have been followed-up in median 57 months (IQR = 24–60). During this period, 21
(67.7%) patients switched at least one antiretroviral drug, including two (6.5%) and three
(9.7%) who switched to a PI-based and an integrase inhibitor-based regimen respectively. A
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total of 10(32.3%) patients died and 4(12.9%) were LTFU. The 36 and 60-months survival
rates were 68.5% and 64.9%, respectively. Among the 17 patients remaining in care, six
(35.3%) had an undetectable viral load (<50 c/mL) and for the 11 others, the viral load ran-
ged from 2.8 to 5.6 log10 c/mL. Twelve patients were receiving lopinavir at the time of first
genotype, five(42%) had a genotypic susceptibility score (GSS)�1 and 4(33%) a GSS >2.
Conclusions
The 36-months survival rate among ART-experienced HIV-2 patients with drug-resistant
viruses is below 70%,lower than in HIV-1. There is urgent need to improve access to sec-
ond-line ART for patients living with HIV-2 in West Africa
Introduction
HIV-2 is responsible for a localized AIDS epidemic that mainly affects the West African region
[1–3]. The therapeutic strategy for people living with HIV-2 remain challenging, due to the
intrinsic resistance of this virus to non-nucleoside reverse transcriptase inhibitors (NNRTI)
and fusion inhibitors, as well as the suboptimal response to some protease inhibitors (PI) [4–
6].
In absence of randomized controlled trial, there is no consensus on the therapeutic care of
people living with HIV-2 [7,8]. The previous national ART guidelines of West African coun-
tries, online with WHO 2010 guidelines, recommended the initiation of a boosting lopinavir/
r-based regimen as the preferred option or a three-NRTI based regimen as alternative [9]. The
current British, French and USA antiretroviral (ART)-guidelines recommend initiating two
NRTI associated with one boosted PI or with one integrase strand-transfer inhibitor (INSTI),
and excluded the use of three NRTI as first-line regimen in patients living with HIV-2 [10–12].
More recently, the 2019 WHO guidelines recommended Dolutegravir (DTG) in combination
with a nucleoside reverse-transcriptase inhibitor (NRTI) backbone as the preferred first-line
regimen for people initiating ART, thus without any difference between those living with
HIV-1 and HIV-2 [13]. However, the implementation of this recommendation in low- and
middle-income countries, especially those with double circulation of HIV-1 and HIV-2 is
ongoing slowly and DTG-based regimen were mainly prescribed to third-line patients in refer-
ral centers [14].
In case of virologic failure, HIV-2 patients were enrolled for three months in an enhanced
adherence counselling program. If at the end of this period the viral load remained unsup-
pressed, the patient was eligible to switch treatment. In 2016, West African and European
guidelines on the management of treatment failure recommended for HIV-2 patients initially
receiving three NRTIs or a LP/r-based regimen as first line, to switch to darunavir (DRV) or
raltegravir (RAL) / Dolutegravir (DTG) in combination with NRTI backbone [14]. With the
recent recommendation of DTG as preferred first-line regardless of HIV type, the preferred
second line recommended by WHO and currently endorsed by West African countries is now
LP/r based regimen for HIV-2 patients [13].
Thus management of virologic failure in HIV-2 patients remain challenging despite the
guidelines revision, due to the limited options (NRTI, boosted PI) available, while an increas-
ing number of studies reported virologic failure and resistance-associated mutations to NRTIs,
PIs and RAL [15–21]. These multiple resistances jeopardize the efficacy of second line HIV-2
treatment, with multidrug resistance needing boosted darunavir plus raltegravir based
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regimen in resource-limited settings where HIV-2 viral load and genotypic resistance tests are
neither routinely available nor affordable.
There is few data reporting experience of therapeutic care and describing long-term out-
come of HIV-2-infected individuals experiencing virologic failure in resource-limited settings.
Such data will be useful to orient clinicians and decision makers in the management of treat-
ment switches in HIV-2 patients with treatment failure. This survey aimed to describe the
sequence of ART regimens use, and the 5-years outcomes among HIV-2 patients harboring
drug-resistant viruses in Côte d’Ivoire.
Materials and methods
Study design, population and settings
A clinic-based cohort study was initiated in January 2012 within the International epidemio-
logical Database to evaluate AIDS (IeDEA) in West Africa [22]. The eligibility criteria for this
cohort were assessed during a cross-sectional survey conducted to describe virologic failure
and drug resistance mutations among HIV-2-infected individuals receiving ART and followed
up in six HIV clinics in Abidjan, Côte d’Ivoire [15]. Based on the results of this cross-sectional
survey presented elsewhere [15], adults living with HIV-2, experiencing virologic failure, and
harboring at least one drug resistance mutation, were included and followed up from 2012 to
2017.
Ethics consideration
The protocol of the IeDEA west Africa collaboration cohort was reviewed and approved in
Côte d’Ivoire by the National Ethic Committee for life Science and Health (CNESVS:
IORG00075). Prior to the initial enrolment in the cohort, each participant was given compre-
hensive information on the study protocol and procedures, and had to provide a written con-
sent before being included.
HIV-2 standard of care in Côte d’Ivoire
According to the national guidelines of Côte d’Ivoire at the time of study in 2012, ART was ini-
tiated in people living with HIV symptomatic stage 3–4 or asymptomatic with CD4 <350
cells/mm3. In case of HIV-2 or HIV1&2, the preferred first line option was 2 NRTI plus
boosted Lopinavir. Three-NRTI-based regimen was considered as alternative option (if CD4
cell counts > 200 cells/mL or Lopinavir contraindication/intolerance) [14]. In case of virologic
failure, HIV-2 patients should receive the most appropriate ART regimen available, with the
guidance of the national referral center for adults living with HIV (Unit of Infectious and
Tropical Diseases Treichville University teaching hospital) [14].
Study procedures
The follow-up consisted in the administration of a standardized questionnaire allowing collec-
tion of clinical (AIDS events and Non-AIDS severe morbidity), biological (CD4 count, viral
load) and therapeutic (switches second line, salvage ART regimen) data, during routine fol-
low-up visits.
Biological procedures
A comprehensive description of the biological procedure has been published [15]. Briefly, viro-
logic failure was defined as plasma HIV-2 RNA above 50 copies/mL using a real-time PCR
assay [23]. Genotypic resistance tests (protease and reverse transcriptase sequencing) were
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performed using an in-house method [15]. The interpretation was based on the HIV French
resistance algorithm update of September 2017, available at http://www.hivfrenchresistance.
org/index.html. A genotypic susceptibility score (GSS) was generated for each patient based on
the results of genotypic analyses. In 2017, a blood sample was collected from each participant
presenting at the HIV clinic, for a routine follow-up visit or returning to care after a successful
tracking process. This blood samples allowed performing a viral load and an additional CD4
count.
Outcomes and variables
The main outcomes considered were being alive, dead or LTFU. Considering LTFU like a
proxy of death, a variable combining death and LTFU was defined.
Death was defined as being reported dead in the medical records of the HIV clinic or being
declared dead by a close relative or a family member. A participant was considered alive if he
presented for follow-up visit during the year 2017 or if he was successfully contacted during
the active tracking process. The participants who did not showed up at HIV clinic for more
than three months, were not known as alive, transferred out or deceased, and were not success-
fully tracked (phone calls and home visits when allowed in the initial consent form) were con-
sidered LTFU.
Statistical analyses
Data analysis was conducted using STATA1 version 14.0, Stata Corp, College Station, Texas
USA. Kaplan Meier curve was used to estimate survival rate and Logrank test was used to com-
pare survival between the two groups.
Results
Baseline characteristics
Among the 31 participants included in the study, 28 (90.3%) were receiving a PI-based regi-
men, 2 (6.5%) a three-NRTI-based regimen and 1 (3.2%) a raltegravir-based regimen. The
median age at enrolment was 50 years (IQR = 46–54 years) and 20 patients were men (64.5%).
At enrolment, the median baseline CD4 count and viral load were 456 cells/mm3 (IQR = 256–
751) and 3,700 c/mL (IQR = 663–7797), respectively. The initial genotypic analyses retrieved
PI resistance mutations (at least one) in 26 (83.9%) participants and NRTI resistance muta-
tions in 21 (67.7%) participants. The GSS was<2 for 14 (45.2%) patients and>2 for 10
(32.3%) others (Table 1).
Follow up characteristics
The cumulative follow-up duration was 1327 person-months with a median duration of 52
months (IQR = 24–59). During this period, 21 (67.7%) patients switched at least one antiretro-
viral drug, including two (6.5%) and three (9.7%) who switched to a PI-based and an INSTI-
based regimen respectively. At the censured date, 17 (55.0%) patients remained in care, while
10 (32.3%) were dead and 4 (12.9%) were LTFU. The last median CD4 count were 150 cells/
mm3 (IQR = 117–218) and 143 cells/mm3 (IQR = 39–340) among patients dead and LTFU,
respectively. Among those still in care during follow up, the 12, 36 and 60-months survival
rates were 86.8%, 68.8% and 64.9% respectively (Fig 1). Neither gender (HR = 1.57, p = 0.484)
nor age>50 years (HR = 0.59, p = 0.421) were associated with mortality.
Among the 17 patients remaining in care, six (35.3%) had an undetectable viral load (<50
c/mL) and for the 11 others, the median viral load was 4,334 [859–87,523] c/mL, ranging from
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Table 1. Follow-up characteristics of antiretroviral-experienced HIV-2-infected patients with identified resistance mutations from 2012 to 2017.
Alive Death/LTFU Total p-values
n = 17 (55%) n = 14 (45%) n = 31
Follow-up duration, months, Median [IQR] 60 [58–61] 19 [12–35] 57 [24–60] 0.001
Baseline CD4 count cells/mm3
Median [IQR] 445 [266–675] 504 [256–855] 456 [256–751] 0.489
�350 6 (35.3) 5 (35.7) 11 (35.5)
350–500 4 (23.5) 1 (7.2) 5 (16.1)
�500 7 (42.2) 7 (50.0) 14 (45.2)
Missing 0 (0.0) 1 (7.1) 1 (3.2)
Last CD4 count cells/mm3
Median [IQR] 281 [193–321] 150 [113–278] 230 [120–321] 0.202
�350 13 (76.4) 11 (78.7) 24 (77.4)
350–500 2 (11.8) 1 (7.1) 3 (9.7)
�500 2 (11.8) 1 (7.1) 3 (9.7)
Missing 0 (0.0) 1 (7.1) 1 (3.2)
Viral load at inclusion c/mL
Median [IQR] 730 [372–4103] 5992 [3700–16716] 3700 [663–7797] 0.007
Viral load at closing date c/mL
Median [IQR] 859 [0–9082] NA 859 [0–9082]
ARV regimen at enrollment
PI-based 17 (100.0) 11 (78.6) 28 (90.3) 0.568
3 NRTI-based 0 (0.0) 2 (14.3) 2 (6.5)
Raltegravir-based 0 (0.0) 1 (7.1) 1 (3.2)
ARV drug switch (at least one) 12 (70.6) 9 (64.3) 21 (67.7) 0.270
To darunavir� 0 (0.0) 2 (14.3) 2 (6.5)
To raltegravir� 2 (11.8) 1 (7.1) 3 (9.7)
Genotypic susceptibility score 0.933
<2 8 (47.1) 6 (41.9) 14 (45.2)
�2 5 (29.4) 5 (35.7) 10 (32.3)
Not available 4 (23.5) 3 (21.4) 7 (22.5)
IQR = interquartile range, LFTU = lost to follow-up, PI = protease inhibitor, NRTI = nucleoside reverse transcriptase inhibitor
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584 to 372,346 c/mL (Table 2). Twelve of these patients were receiving lopinavir at time of first
genotyping analysis, eight (47.1%) had a GSS <2 and five (29.4%) a GSS>2. Their last median
CD4 count was 281 cells/mm3 (IQR = 209–351), not significantly different to those who died
or were LTFU (p = 0.20). none of participants CD4 increased after switch or after the first viro-
logic failure.
Among the 10 patients declared dead, 6 (60.0%) had CD4 count<200 cells/mm3, 7 (70.0%)
had a boosted PI in their last known ART regimen, five (50.0%) had a GSS <2 and 7 (70.0%)
changed at least one drug in their ARV regimen at least once after the diagnosis of drug resis-
tance mutation. Regarding treatment, 5 of them switched to an unappropriated and non-effec-
tive ART regimen according to the genotypic resistance test. three of them were maintained
on boosted-lopinavir as a compassionate treatment until they died. Two of them received a
Table 2. Five-years ART-response among HIV-2 infected patients surviving after experiencing treatment failure with identified drug resistance mutations in Côte
d’Ivoire, West Africa.
Patients demographics ART Response in 2012 Genotypic analyses in 2012 ART Response in 2017
ID Age
(years)












PAT-S01 51 M AZT/3TC/LPV/r 106 340 M184V V47A, V62A 1 ABC/3TC/LPV/
r
281 859
PAT-S02 53 M ABC/3TC/LPV/r 919 713 M184V I54M 2 TDF/3TC/
LPV//r
209 4,334
PAT-S03 56 M AZT/3TC/LPV/r 675 3085 M184V, S215Y V47A, I82M, L90M 0 AZT/3TC/LPV/
r
351 372,346
PAT-S04 30 F AZT/3TC/LPV/r 119 663 NA V47A, NA AZT/3TC/LPV/
r
291 87,523
PAT-S05 58 M AZT/3TC/LPV/r 545 149 NA Wild-Type NA TDF/3TC/LPV/
r
362 -
PAT-S06 60 F ABC/ddI/LPV/r 791 4103 M184V NA NA TDF/3TC/LPV/
r
79 13,457
PAT-S07 33 M SQV/LPV/r 141 33287 Q151M I50V, I54M, L90M 0 TDF/3TC/
DRV/r/RAL
214 -







PAT-S09 49 M ddI/ABC/LPV/r 751 1471 M184V V47A, L99F 2 TDF/3TC/
DRV/r
256 1,535
PAT-S10 54 M AZT/3TC/LPV/r 357 5156 Wild-Type Wild-Type 3 AZT/3TC/LPV/
r
103 2,337
PAT-S11 60 M ABC/ddI/LPV/r 445 3016 Q151M, M184V,
S215F
I54M, I84V 0 ABC/ 3TC/
TDF/ DRV/r
193 9,082
PAT-S12 50 M TDF/FTC/LPV/r 606 193 M184I Wild-Type 2 ABC/3TC/LPV/
r
120 -
PAT-S13 53 M AZT/3TC/LPV/r 157 395 M184V V47A 1 AZT/3TC/LPV/
r
297 223,827
PAT-S14 43 F TDF/FTC/LPV/r 336 91 M184V Wild-Type 2 TDF/3TC/LPV/
r
774 -
PAT-S15 55 M AZT/3TC/LPV/r 712 372 NA V47A NA AZT/3TC/
DRV/r
855 -
PAT-S16 53 M AZT/3TC/LPV/r 266 730 M184V, S215Y V47A, V62AI 0 AZT/3TC/LPV/
r
321 584
PAT-S17 49 F TDF/FTC/LPV/r 466 5146 K65R, N69S, M184V V47A 0 TDF/3TC/LPV/
r
292 685
NA: Not amplified; ID = participant identifier; ART = antiretroviral therapy; VL = viral load; NRTI = Nucleoside reverse transcriptase inhibitors; PI = protease
inhibitors; GSS = genotypic susceptibility score
https://doi.org/10.1371/journal.pone.0236642.t002
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non-recommended regimen for HIV-2 based on Atazanavir although LPV/r-based regimen
was effective.
Discussion
In this observational cohort study conducted in Côte d’Ivoire, we reported after 5 years of
diagnosis of at least one drug resistance mutation to first-line ART regimen among HIV-2
patients, high mortality and lost to follow-up. Half of HIV-2 patients were not retained in care
5 years after the diagnosis of drug resistance mutation.
This high rate of mortality could be explained by the lack of access to second-line therapy
for these patients in resource-limited settings. According to the US and French ART guide-
lines, only integrase inhibitors such as raltegravir, elvitegravir or dolutegravir or the CCR5
antagonist maraviroc (MVC) could be used as a second-line therapy among HIV-2 patients
[24–28]. However, in most west African countries, these antiretroviral molecules are still
scarcely available. In our study only three (9.3%) patients diagnosed with drug resistant viruses
switched to the INSTI raltegravir, none of them received dolutegravir. Among the patients
dead or LTFU, only one (7.1%) and two (14.2%) switched to an INSTI and to the PI darunavir,
respectively. For these latter patients, the median last known CD4 count was 150 cells/mm3,
indicating that more than half of them were in advanced HIV disease according to the immu-
nologic definition [29]. Increase the availability of more efficient antiretroviral drugs like inte-
grase inhibitors is critical for patients living with HIV-2 for whom the therapeutic arsenal is
limited specifically for patients harboring viruses with drug resistance mutations [15].
In resource-limited settings, there was no clear sequence of ART regimen use for the treat-
ment of HIV-2-infected individual experiencing virologic failure [14]. This lack of clear guide-
lines may be the consequence of limited data on the switch of treatment among HIV-
2-infected patients, the lack of routine implementation of validated tool for viral load monitor-
ing, the absence of definition of immunological failure and the paucity of data regarding drug
resistance mutations [7,8,23,30–32]. Since the mortality remains high among HIV-2 patients
receiving ART [33,34], it is critical to address all the gaps and need in terms of data in order to
propose clear guidelines for the treatment of HIV-2 patients experiencing virologic failure.
In the present study, six of the 17 patients remaining in care had no active antiretroviral
drug in their regimen. In fact, salvage regimen for those patients with a good GSS should use
boosted-darunavir and DTG which remains active in some cases of resistance to the first gen-
eration of INSTI [21,35]. Thus, in this context, genotypic resistance tests are needed in order
to prevent DTG from being functional monotherapy which will result to the selection of DTG
resistances. Unfortunately, according to the GSS of the patients of the present study it seems
that DTG will not be sufficient and additional new drugs are needed, such as maraviroc or
broad-spectrum neutralizing antibodies (Ibalizumab) [36–38]. Unfortunately, in our study
population, among the 10 patients with no active ARV drug (GSS = 0), four died, arguing for
the need of new therapeutic options for HIV-2 infection.
Since 2018, WHO guidelines recommend tenofovir plus lamivudine plus dolutegravir
based regimen as the preferred first-line option according to expert opinion, pilot studies and
in vitro data [39]. This will change the management of HIV-2-infected patients with the use of
boosted-PI such as lopinavir or darunavir with an optimized NRTI-backbone in second-line
[21,27,39–41]
Study limitations and strengths
Although the study was conducted in the HIV clinics with a proper documentation of patient’s
follow-up, the main limitation is the lack of documentation of the cause of death. For all the
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patients who were not reported dead at the HIV clinic, it was not possible to identify the clini-
cal cause of death, as the only information available in the official death certificate was “dis-
ease”. In addition, viral load measurement was not routinely performed and only two
measures (2012 and 2017) were available for the analysis, making it impossible to describe the
evolution according to the switches of antiretroviral drugs during the five years of follow-up.
Furthermore, this study presents data of a small population and the estimates may suffer from
lack of statistic power. However, to our knowledge, this is one of the first report on treatment
outcomes among HIV-2 patients who experienced virologic failure with at least one drug resis-
tance mutation in West Africa. Data on long-term follow-up among HIV-2 patients are also
limited and this study highlights the challenge to determine the sequence of ART use in this
population.
Conclusions
Our data call for the urgent access to second-line and third-line therapy among HIV-2
patients. Clinical trials for HIV-2-infected patients harboring multi-drug resistant viruses
should be conducted in both resource-limited settings and western countries. Results from the
first randomized controlled trial on HIV-2 (FIT-2) Expected in 2020, will be helpful to define a
sequence of ART initiation among HIV-2 patients.
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